BridgeBio Oncology (BBOT) Form 3: Director Reports No Holdings

Michelle Doig, identified as a Director of BridgeBio Oncology Therapeutics, Inc. (BBOT), filed an initial Form 3 reporting a 08/11/2025 event.

Rhea-AI Filing Summary

Michelle Doig, identified as a Director of BridgeBio Oncology Therapeutics, Inc. (BBOT), filed an initial Form 3 reporting a 08/11/2025 event. The filing, signed by an attorney-in-fact on 08/18/2025, states that no securities are beneficially owned by the reporting person. The submission includes a Power of Attorney exhibit and confirms the Form 3 was filed by a single reporting person.

Positive

• Form 3 was filed, establishing required Section 16 disclosure
• No beneficial ownership reported, removing immediate insider-holding complexity

Negative

• None.

Insights

Corporate Governance Analyst

Director filed an initial Form 3 and reported no holdings.

The filing documents that a newly reported director, Michelle Doig, has no beneficial ownership of the issuer's securities as of the 08/11/2025 event date. The form includes an Exhibit 24 Power of Attorney and was executed by an attorney-in-fact on 08/18/2025.

This record is primarily administrative: it establishes reporting status and confirms there is currently no disclosed insider stake to monitor. Investors or compliance teams may note the absence of holdings and the use of a power of attorney for a short-term administrative action.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Michelle Doig report on her Form 3 for BBOT?

The report states no securities are beneficially owned by Michelle Doig and includes Exhibit 24 (Power of Attorney).

When is the event date reported on the Form 3 for BBOT?

The event date listed on the Form 3 is 08/11/2025.

Who signed the Form 3 for Michelle Doig?

The Form 3 was signed by an attorney-in-fact, Aaron Chan, on 08/18/2025.

Does this Form 3 indicate insider ownership for BBOT?

No. The filing explicitly states no securities are beneficially owned by the reporting person.

Was the Form 3 filed by one or more reporting persons?

The form indicates it was filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 05:19 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

DOIG MICHELLE

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.